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Abstract The three-dimensional structure of cyclopeptolide 
HUN-7293, a naturally-occurring inhibitor of cell adhesion mol- 
ecule expression, has been determined from nuclear magnetic 
resonance data recorded in solution and from X-ray diffraction 
analysis of single crystals. The backbone conformation of HUN- 
7293 is characterized by two cis-peptide bonds in both the solution 
and crystalline state. Differences between the solution and crystal 
structure are visible for the orientation of some side chains and 
the strength of two transannular hydrogen bonds. Such structural 
information helps to provide insight into the molecular architec- 
ture of HUN-7293 on the atomic level and opens the way for 
structure-based modifications of this novel inhibitor of cell adhe- 
sion molecule expression. 
Key words: Conformation; Adhesion molecules; ICAM-1; 
VCAM-1; Nuclear magnetic resonance; X-Ray crystallography 
I. Introduction 
Cell adhesion molecules uch as ICAM-1, VCAM-1, and 
E-selectin play a critical role in the immune response by regulat- 
ing leucocyte migration and cell-to-cell interaction [1,2]. Modu- 
lation of these interactions by blocking or inhibiting adhesion 
molecule expression would have a therapeutic potential in a 
variety of inflammatory diseases. While searching for low mo- 
lecular weight inhibitors of inducible adhesion molecule xpres- 
sion, we identified the naturally-occurring compound HUN- 
7293 in a HaCaT keratinocyte-based ICAM-1 ELISA [3]. 
HUN-7293 also potently suppresses cytokine-induced xpres- 
sion of VCAM-1 on human endothelial cells [4]. The compound 
is a fungal product [5] and belongs to a novel class of seven- 
membered cyclic peptolides that contains several uncommon 
constituents (i.e. D-2-hydroxy-4-cyanobutyric a id, NI ' -  
methoxy-N-methyltryptophan and the novel 'C9-amino acid' 
D-propylleucine). A schematic representation of the chemical 
constitution of HUN-7293 is shown in Fig. 1. 
Macrocyclic natural products have attracted wide interest for 
the development ofdrugs in many disease areas [6-8]. However, 
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major problems are associated with these compounds either 
when they are peptidic in nature resulting in reduced plasma 
stability, or stereochemically complex, rendering a total synthe- 
sis very difficult. As a consequence, much effort has been ex- 
pended to design and synthesize small molecular mimetics with 
equal potency and increased chemical stability. Information on 
the three-dimensional conformation of a compound provides 
the rational basis for applying molecular modelling techniques 
[9-10]. To gain insight into the structural basis for the biological 
activity of HUN-7293, we determined its three-dimensional 
structure both in solution and in single crystals by NMR spec- 
troscopy and X-ray diffraction techniques, respectively. This 
approach revealed that HUN-7293 adopts a single well-defined 
conformation i  solution, which is very similar to that found 
in single crystals. 
2. Materials and methods 
2.1. NMR spectroscopy and solution structure determination 
All spectra were recorded on either a Bruker DMX500 or AM500 
spectrometer operating at 500 MHz. Peptolide solutions were typically 
2-5 mM in 80% CDCI3/20% (D6)DMSO or 70% MeOH/30% H20 
mixtures. A constant temperature of 4°C or 15°C was maintained 
during experiments for ROESY [11] spectra (mixing time = 150 ms), 
from which structural information was extracted. Isolation and purifi- 
cation of HUN-7293, together with the spectroscopic characterization, 
will be published elsewhere. 
Assigned peaks in ROESY spectra were integrated using XEASY 
[12] and converted into interatomic distances using CALIBA [13]. Dihe- 
dral restraints and stereospecific assignments were incorporated during 
the process of structure refinement after inspection of structures with 
low energy and low residual violations of the distance restraints using 
GLOMSA [13]. The procedure for calculating structures followed 
standard simulated annealing protocols as described in the X-PLOR 
Manual 3.0 [14]. A starting structure for X-PLOR runs was generated 
from DIANA [13] based on a modified library containing the uncom- 
mon amino acids N-methylalanine (MALA), D-2-hydroxy-4-cyanobu- 
tyric acid (DGCN), N-methylleucine (MLEU), Nl'-methoxy-N-meth- 
yltryptophan (MTO). For simplicity reasons, the 'C9-amino' acid D- 
propylleucine was substituted by leucine since no structurally-relevant 
constraints have been found for any protons beyond the D-methyl 
groups. The absolute configuration of the Ca-atoms of LEU_5 and 
DGCN_2 was of the L- and D-type, respectively, asdetermined by chiral 
phase gas chromatography (data not shown). For all other esidues the 
L-type was assumed, and later confirmed, by the X-ray diffraction 
analysis described below. 
2.2. X-Ray crystallography 
Crystals were obtained from a saturated solution in 80% DMSO/20% 
glycerol after seeding and cooling from 60°C to room temperature at 
a rate of l°C/h. The crystals were collected by filtration, washed with 
water and dried at room temperature in vacuo (10 -3 mbar). The space 
group was P2~2~2~, cell dimensions a = 10.36 A, b = 23.69 A, c = 25.31 
A, V = 6212 A 3, Z = 4 (one molecule per asymmetric unit), de,to = 1.128 
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Fig. 1. Schematic representation f HUN-7293. 
g. cm -3. 10096 reflexions were measured out to a resolution of 0.89 A 
(0 < 60 °, CuK~ radiation), which yielded 5133 unique reflexions 
(Ri,, = 0.082), of which 3151 with IFoI>4 o'(F). The intensities were 
corrected for a slow decay of the crystal during measurement (15.7% 
in 154 h of exposure time). No absorption correction was applied 
(/.t = 8.9 cm-J). 
3. Results 
3.1. Preliminary characterization by NMR 
Initial inspection of ROESY spectra showed that HUN-7293 
exists in CDC13/DMSO solutions predominantly in one confor- 
mation (>90%). The same observation was made for protic 
solvent mixtures of MeOH/H20, while a higher degree of a 
second conformation (20%) was found in pure CDC13 solu- 
tions. Prominent structural features of the major conformation 
are two cis-peptide bonds between residues PrLEU_3 and 
MLEU_4 as well as LEU_5 and MTO_6 (Fig. 2), and large 
coupling constants 3JHN ~ and 3j~ for some of the residues 
(Table 1). In addition, there are strong chemical shift shielding 
effects for the fl~ proton of LEU_5. These results, together with 
the observation of a slowly exchanging amide proton of 
PrLEU_7, indicated that the compound exists in a rather fixed 
conformation under the conditions tudied. 
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3.2. NMR structure determination 
For calculation of the solution structure of HUN-7293, a 
total number of 78 NOE-derived istance restraints were ex- 
tracted from ROESY spectra; 27 intraresidual, 26 sequential 
(]i-j] = 1), and 25 medium range (1 < ]i-j] < 4). In addition, 5 
angle restraints (20, 3 Z0 were derived from measurement of 
coupling constants and inspection of internuclear distances 
using GLOMSA [13]. A set of 20 individual structures was then 
calculated on the basis of these restraints using standard simu- 
lated annealing protocols in X-PLOR. Most of the structures 
(19/20) converged to the same fold with no violations to 
the experimental distance restraints greater than 0.35 A and 
dihedral restraints greater than 5 ° . The atomic root-mean- 
square deviation of ten structures with lowest energies 
(<20 kcal'mol -~) was 0.08 A and 0.44 A for backbone 
atoms and heavy atoms, respectively. The structure can thus be 
described as well defined for both the backbone and some of 
the sidechain conformations (Fig. 3). 
3.3. Solvent dependence of the 3D structure 
A pertinent question in our study was whether the three- 
dimensional structure of HUN-7293, determined in aprotic 
apolar solution, is also relevant under physiological conditions. 
To address this issue, we checked its conformational properties 
qualitatively in a polar and protic solvent mixture (MeOH/ 
H20: 70%/30%) since the compound is not soluble in water. 
Several lines of evidence suggest that a conformation very sim- 
ilar to the one calculated for organic solvent mixtures can be 
assumed to also exist in aqueous olutions. This assumption is 
based on the experimental observations of the same two cis- 
peptide bonds (Fig. 2), the similar coupling constants (Table 1), 
the characteristic chemical shift for the fl~ proton of LEU_5 
(-0.61 ppm in CDC13/DMSO; -0.71 ppm in MeOH/H20 ) in- 
duced by ring current shift effects mediated by stacking interac- 
tions with the neighboring MTO_6, and the slow exchange of 
NH of PrLEU_7 with bulk solvent. 
3.4. X-Ray structure analysis 
Crystallization of HUN-7293 proved to be cumbersome ini- 
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Fig. 2. Part of a ROESY spectrum of HUN-7293 acquired in (A) 70% CD3OD/30% D20 and (B) 80% CDC13120% (D6)DMSO. The negative 
cross-peaks between the Call resonances of residues 3, 4 and 5, 6 indicating the two cis-peptide bonds are labelled according to the residue position; 
the additional positive cross-peak (Ex) in (A) is due to chemical exchange ofthe solvent OH resonances. 
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Fig. 3. Stereo-picture of the solution structure of HUN-7293. The backbone atoms (Ccq C, N) of 10 selected structures with lowest total energies 
(< 20 kcal-mol -~) have been best fit superpositioned with a root-mean-square deviation of 0.08/~. The backbone is shown in heavy lines and side 
chain atoms are shown in grey (note that the PrLEU residues have been truncated for structure calculation purposes by leucine residues in the NMR 
study). The final values of each term of the target function were:  F ro  t = 22.0 + 5.6 kcal.mol-~; Fbond s = 2.8 + 0.6 kcal.mol-~; Fang le  = 8.1 + 2.8 
-~  _ + - _ + - _ + - kcal.mol ; F improper  - 1 .0  _ 0.8 kcal'mol ; Fvaw - 2.8 _ 0.4 kcal.mol , F, oe - 7,4 _ 1.2 kcal.mol ; Fdh~ = 0.02 --+ 0.03 kcal'mol -~. 
tially, and as a consequence the structure determination was 
carried out after the high resolution NMR structure in solution 
was completed. As described above, well-diffracting crystals 
could be grown from a solvent mixture containing 80% DMSO. 
This is consistent with the observation made in the solution 
studies which showed that HUN-7293 can be stabilized in one 
conformation by an aprotic solvent such as DMSO. 
The structure was solved by direct methods using SHELXS- 
86 [15] and refined by Full Matrix LS-methods (SHELX-76, 
[16]) to an R-factor of 0.0928 for 751 structural parameters 
(anisotropic temperature factors for all heavy atoms, H-atoms 
'riding' on the attached atom) for 3151 structure factors with 
IFol>4 a(F) (Rw = 0.1046, s = 1.308, average shift/esd in final 
cycle = 0.15). In the final difference Fourier there was no elec- 
tron density above 0.33 e 'A  -3 
During the refinement a solvent molecule of DMSO was 
detected in the electron density and subsequently included in 
the calculations. A positional disorder of the Nt'-O-methylin- 
dol moiety of MTO was also found: the fragment existed in two 
orientations flipped by 180 ° around Z2, thus having a common 
DMSO 
~.~ , ~MTO_6 ~ , 
P r L E U _ 3 ~  
Fig. 4. ORTEP stereo-view of the crystal structure of HUN-7293. Non-hydrogen atoms are shown as 25% probability thermal ellipsoids. The 
transannular hydrogen-bonds are shown by thin lines. 
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Fig. 5. Stereo-diagram indicating the crystallographic packing of HUN-7293. The backbone is highlighted by heavy lines. 
plane for the two positions. (For clarity only one position with 
2"2 = 81° is shown in the Figures.) 
approach also verified the R-chirality of the C7 in the side 
chains of PrLeu. 
3.5. Crystalline conformation 
An ORTEP stereo-view of the molecular conformation of 
HUN-7293 is depicted in Fig. 4, indicating the 25% probability 
thermal vibration ellipsoids. It clearly shows the well-defined 
positions of the cyclic backbone and the growing thermal vibra- 
tion of atoms with increasing distance from the backbone, most 
prominent for the extended PrLEU sidechains. The backbone 
conformation is very similar to the solution structure and is 
characterized by the two eis-amides (PrLEU_3 to MLEU_4, 
and LEU_5 to MTO_6), and the two strong transannular hy- 
drogen bonds adding stability to the backbone (Table 2), Also 
shown in Fig. 4 is the solvent molecule DMSO, whose oxygen 
is in hydrogen bonding distance to the NH of LEU_5, d(O...H- 
N) = 3.07 A. Analysis of the intermolecular contacts revealed 
no other short interactions apart from the hydrogen bond men- 
tioned above; in fact, no other hydrogen bonds would be pos- 
sible since no additional exposed H-bond donors exist. The 
crystal packing diagram is shown in Fig. 5. 
The absolute configuration of HUN-7293 was assumed from 
the known chirality of its constituent L-LEU_5, identified ex- 
perimentally (data not shown). The X-ray analysis proved that 
all s-amino acids in the compound have L-configuration, in 
particular the novel PrLEU and MTO amino acids. The 2- 
hydroxy acid DGCN_2, however, has D-configuration. This 
4. Discussion 
The structure of HUN-7293 is best described as an 'erected 
Cobra-head', depicted in Fig. 3. One can also think of an image 
where the backbone of the molecule follows the outline of a 
hand with the fingers closed and the palm forming a hollow. 
The cis-peptide bond between residues 5and 6 would be located 
at the wrist, while the fingertips would point towards residues 
2 and 3. This overall bent structure allows residues DGCN_2, 
LEU_5 and MTO_6 to come in close proximity to one another 
on one face of the peptide. We also note that both 'C9-amino' 
acids point into the same direction on the opposite face of the 
molecule. The calculated structures atisfy other experimental 
observations than those used for the structure calculations. A
hydrogen bond observed between the NH of PrLEU_7 and 
C = O of MLEU4 in both the solution and the crystal struc- 
ture explains the slow exchange of this proton with bulk sol- 
vent. A second hydrogen bond between NH of PrLEU_3 and 
C = O of PrLEU_7 is present in the crystal but not the solution 
structure, and consequently the proton involved was found to 
rapidly exchange with bulk solvent in solution. Furthermore, 
strong ring current shift effects for the fl~ proton of LEU_5 
indicate stacking interactions with the indole moiety of 
MTO_6, as seen in both the crystal and solution structure. 
u5  
LEU_4 
Fig. 6. Best fit superposition of the backbone of the crystal structure (heavy 
of HUN-7293. 
i LEU-4 
lines) on the energy minimized average solution structure (thin lines) 
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Table 1 
Comparison of coupling constants indifferent solvents: A (80% CDC13/20% (D6)DMSO), B (70% CD3OH/30% H20) fll and f12 refer to the low-field 
or high-field component of a fl-methylene group, respectively 
Residue Solvent A Solvent B* 
3JHN ~ (Hz) 3j~, (Hz) 3J~z (Hz) 3JHN ~ (Hz) 3j~, (Hz) 3J~2 (Hz) 
2 3.0 9.5 3.5 
3 9.8 8.0 6.0 9.4 8.0 6.0 
4 11.5 3.5 11.5 4.0 
5 6.4 12.0 3.5 6.0 3.5 
7 9.8 9.5 5.0 10.3 9.0 5.0 
*Fully deuterated solvents have been used for measurement of 3j~ and 3J~ 2. 
Table 2 
Hydrogen bonds observed in the crystal structure of HUN-7293 
D-H...A d(D...A) d(H...A) a(D_H...A) 
(•) (A) (degree) 
N(7)-H...O = C(4) 2.80 1.75 165 
N(3)-H...O = C(7) 2.82 1.77 164 
Inspection of the structure also provides insight into possible 
functional regions of the molecule. In general, there are only 
a few polar groups found on the surface of the molecule which 
are accessible for a putative hydrogen bond acceptor/donor f 
the HUN-7293 receptor. One possible hydrogen-bond donor is 
the NH group of residue LEU5,  and interestingly, a solvent 
molecule was found to be in hydrogen-bonding distance in the 
crystal structure. Other polar groups found on the surface of 
the molecule are the carbonyl groups of MALA 1, DGCN_2, 
LEU5 and MTO_6 which represent possible hydrogen bond 
acceptors. In addition, the 4-cyano group of DGCN_2 is sol- 
vent exposed and thus appears to be a possible anchor for 
ligand receptor interactions. 
Availability of both a solution and crystal structure of HUN- 
7293 opens the way for studying potential receptor-induced 
conformational changes of the compound. As shown in Fig. 6, 
both the crystal and solution structure of HUN-7293 are very 
similar. The root-mean-square deviation between the crystal 
and energy minimized average solution structure is 0.37/~ (C, 
N, Ca, Cfl, CN, O) of residues 1-7, and 0.28/k for residues 3 7. 
The larger deviations seen around residue DGCN2 are accom- 
panied by the formation of a hydrogen bond between NH of 
PrLEU_3 and C = O of PrLEU_7 in the crystal structure, 
which is not present in the solution structure. In addition, the 
side-chain of residue 2, which is in close proximity to the side 
chain of residue 6, radiates lightly off from the macrocycle in 
the crystal structure. It is therefore tempting to speculate that 
the observed changes reflect the situation when HUN-7293 
binds to its cognate receptor. Further structural studies on 
HUN-7293 derivatives are needed, however, to exclude the 
possibility that the minor changes een are induced by crystal- 
lographic packing rather than a genuine induced-fit binding 
mode. 
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